

DT02 Rec'd PCT/PTO 0 4 JUN 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By Linda M. Dunb:n	Date Stume 1 2004

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: John M. Beals, et al.)
Serial No.	: 09/856,451) Confirm. No.:) 8155
Filed	: May 22, 2001)
For	: Erythropoietic Compounds)
Docket No.	: X-12553	·)

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE UNDER 35 U.S.C. 371

Commissioner for Patents Mail Stop Missing Parts P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is in response to a Notification of Defective Response dated May 6, 2004, noting the damaged and/or unreadable diskette containing the nucleotide and/or amino acid sequence requirements in the papers filed with the above-identified application.

Enclosed herewith are: 1) a copy of the Notice, 2) an Amendment Directing Entry of Sequence Listing Into The Specification, 3) a computer readable form of the Sequence Listing, 4) a paper copy of the Sequence Listing, and 5) a statement that the contents of the paper and the computer readable form of the Sequence Listing are the same and include no new matter.

Serial No. 09/856,451

The Commissioner is hereby authorized to charge any additional fees that may be required by this Response or credit any amount due to Deposit Account No. 05-0840 for the surcharge required by §1.16(e). An original and two copies of this paper are enclosed.

Respectfully submitted,

Caren D. Geppert

Attorney for Applicants

Registration No. 54,117

Phone: 317-651-4215

Eli Lilly and Company Patent Division/CDG P.O. Box 6288 Indianapolis, Indiana 46206-6288







UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address. COMMISSIONER FOR PATENTS Dox 1450 andria, Vingrus 22313-1450

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATT	Y DOCKET NO
09/856,451	John Michael BEALS	John Michael BEALS X-125	
		INTERNATIONAL APPLICATION NO	
.0-	_	PCT/US99/27801	
511 Lilly and 0 00		I A FILING DATE	PRIORITY DATE
Eli Lilly and Company		11/23/1000	11/30/1009

Lilly Corporate Center Indianapolis, IN 46285

ue-6-6-04

CONFIRMATION NO. 8155 371 FORMALITIES LETTER OC0000000125372511

Date Mailed: 05/06/2004

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- Priority Document
- Copy of the International Application filed on 05/22/2001
- Copy of the International Search Report filed on 05/22/2001
- Copy of IPE Report filed on 05/22/2001
- Preliminary Amendments filed on 05/22/2001
- Biochemical Sequence Diskette filed on 06/25/2002
- Oath or Declaration filed on 05/22/2001
- Biochemical Sequence Listing filed on 06/25/2002
- Copy of references cited in ISR filed on 05/22/2001
- U.S. Basic National Fees filed on 05/22/2001
- Assignment filed on 05/22/2001

Applicant's response filed 06/25/2002 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 04/22/2002 have not been completed.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial or substitute computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing CEVED"

 An initial computer readable form (CRF) of the "Sequence Listing C
 - APPLICANT MUST PROVIDE:





- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

FRANCINE YOUNG

Telephone: (703) 305-3662

PART 1 - ATTORNEY/APPLICANT COPY

U S APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO	ATTY DOCKET NO.
09/856,451	PCT/US99/27801	X-12553

FORM PCT/DO/EO/916 (371 Formalities Notice)